View Financial HealthAcura Pharmaceuticals 배당 및 자사주 매입배당 기준 점검 0/6Acura Pharmaceuticals 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • May 14Acura Pharmaceuticals, Inc. announced delayed 10-Q filingOn 05/13/2026, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • Mar 28Acura Pharmaceuticals, Inc. announced delayed annual 10-K filingOn 03/27/2026, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공고 • Mar 11Acura Pharmaceuticals, Inc. announced that it has received $0.1 million in fundingAcura Pharmaceuticals, Inc. announced a private placement of loan for a principal amount of $100,000 on March 10, 2026. The transaction included participation from returning lender, Abuse Deterrent Pharma, LLC. The company issued a secured promissory note. The note bears interest at 5.25%. The Events of default under the Note include, among other items, bankruptcy events, failure to pay interest and principal when due and such failure continues for 5 days, and if Acura is generally not, or is unable to, or admits in writing its inability to, pay its debts as those debts become due. If any amount payable hereunder is not paid when due (without regard to any applicable grace periods), whether at stated maturity, by acceleration, or otherwise, including upon an event of default, such overdue amount shall bear interest at the rate per annum of 7.5% from the date of such non-payment until such amount is paid in full. The company has received a total principal balance of $9,894,279.공고 • Nov 23Acura Pharmaceuticals, Inc. announced delayed 10-Q filingOn 11/21/2025, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • Sep 04Acura Pharmaceuticals, Inc. announced that it has received $8.694279 million in funding from Abuse Deterrent Pharma, LLCAcura Pharmaceuticals, Inc. announced a private placement of loan for a principal amount of $100,000 on September 3, 2025. The transaction included participation from returning lender, Abuse Deterrent Pharma, LLC. The company issued a secured promissory note. The note bears interest at 5.25%. The Events of default under the Note include, among other items, bankruptcy events, failure to pay interest and principal when due and such failure continues for 5 days, and if Acura is generally not, or is unable to, or admits in writing its inability to, pay its debts as those debts become due. If any amount payable hereunder is not paid when due (without regard to any applicable grace periods), whether at stated maturity, by acceleration, or otherwise, including upon an event of default, such overdue amount shall bear interest at the rate per annum of 7.5% from the date of such non-payment until such amount is paid in full. The company has received a total principal balance of $8,694,279.공고 • Aug 20Acura Pharmaceuticals, Inc. announced delayed 10-Q filingOn 08/19/2025, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • May 23Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Announces Second Meeting with US Food and Drug AdministrationAcura Pharmaceuticals, Inc. reported that on May 15, 2025 the Company and its development partner, AbuseDeterrent Pharma, LLC, had a second meeting with the US Food and Drug Administration (FDA) regarding further development requirements for its drug candidate LTX-03 (hydrocodone bitartrate and acetaminophen) tablets to progress toward a New Drug Application (NDA) submission. LTX-03 uses Acura's LIMITx technology that is designed to provide incrementally lower, non-linear peak drug blood concentrations (Cmax) of hydrocodone as additional tablets are ingested. Subject to the final FDA meeting minutes and further deliberations and analyses by the Companies, expect to conduct one additional human pharmacokinetic study of a single tablet dose of LTX-03 compared to a single FDA Reference Standard drug in the fed and fasted state. This study, designated AP-LTX-310, will commence following production of new clinical supplies of LTX-03. Subject to NDA review, FDA was amenable to describing the unique pharmacokinetic characteristics of LTX-03 in the final approved labeling. FDA advised that a label claim suggesting a lower risk of overdose would not be warranted by pharmacokinetic testing alone. The Company believes a study to support a lower risk safety claim would best be accomplished post-NDA approval, which cannot be assured. FDA indicated the lower 5/325mg and 7.5/325mg dosage strengths of LTX-03 will require a plan to scientifically support those products in the NDA. The company is evaluating whether to conduct such a study for the NDA submission or to study and add these strengths after NDA approval, which cannot be assurance. LTX-03 (hydocodone with acetaminophen) The incidence and severity of side effects, such as nausea, vomiting and respiratory depression, associated with opioid pain relievers, such as hydrocodone, increase with increased blood plasma concentration of the opioid. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements expressed or implied by such forward-looking statements.공고 • May 15Acura Pharmaceuticals, Inc. announced delayed 10-Q filingOn 05/14/2025, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • Mar 27Acura Pharmaceuticals, Inc. announced delayed annual 10-K filingOn 03/26/2025, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공고 • Nov 22Acura Pharmaceuticals, Inc. announced delayed 10-Q filingOn 11/21/2024, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • Aug 10Acura Pharmaceuticals, Inc. announced delayed 10-Q filingOn 08/09/2024, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • May 17Acura Pharmaceuticals, Inc. announced delayed 10-Q filingOn 05/15/2024, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • Apr 02Acura Pharmaceuticals, Inc. announced delayed annual 10-K filingOn 04/01/2024, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공고 • Feb 15Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in fundingAcura Pharmaceuticals, Inc. announced a private placement of loan for gross processed of $250,000 on February 14, 2024. The transaction included participation from returning lender Abuse Deterrent Pharma, LLC. The company issued an unsecured promissory note. The note bears interest at 5.25%, and matures on March 31, 2024, at which time all principal and interest is due. Events of default under the note include, among other items, bankruptcy events, failure to pay interest and principal when due and such failure continues for 5 days, and if company is generally not, or is unable to, or admits in writing its inability to, pay its debts as they become due. If any amount payable hereunder is not paid when due (without regard to any applicable grace periods), whether at stated maturity, by acceleration, or otherwise, including upon an event of default, such overdue amount shall bear interest at the rate per annum of 7.5% from the date of such non-payment until such amount is paid in full. the company received a total of $5,169,279.공고 • Nov 04Acura Pharmaceuticals, Inc. announced delayed 10-Q filingOn 11/03/2023, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • Sep 26Acura Pharmaceuticals, Inc. Announces Retirement and Resignation of Mr. Bruce F. (Toby) Wesson as Member of Board of DirectorsEffective September 22, 2023, Mr. Bruce F. (Toby) Wesson retired and resigned as a member of Board of Directors and the Board of Directors of Acura Pharmaceutical Technologies, Inc. subsidiary. Mr. Wesson has agreed to serve as Director Emeritus following his resignation. In such capacity, Mr. Wesson may attend Board and Committee meetings and participate in the discussion of matters at such meetings, but he will not have voting rights on any such matters. Mr. Wesson has been a member of Board of Directors since March 1998. From January 1991 until June 30, 2011, Mr. Wesson was a Partner of Galen Associates, a health care venture firm, and a General Partner of Galen Partners III, L.P. Prior to January 1991, he was Senior Vice President and Managing Director of Smith Barney, Harris Upham & Co. Inc., an investment banking firm. From May 2006 until June 2016 he served on the Board of Derma Sciences, Inc. From June 1999 until January 2016 he served as director of the Board of MedAssets, Inc. and for over eight years until January 2016 served as Vice Chairman of MedAssets, Inc. Mr. Wesson earned a Bachelor of Arts degree from Colgate University and a Masters of Business Administration from Columbia University. As a member of Acura's Board, Mr. Wesson helped to oversee the transformation of Acura from a troubled generic pharmaceutical manufacturer to an innovative specialty pharmaceutical company.공고 • Sep 02Acura Pharmaceuticals, Inc. Provides Update Related to LTX-03 (Hydrocodone Bitartrate and Acetaminophen) TabletsAcura Pharmaceuticals, Inc. reported that the LTX-03 (hydrocodone bitartrate and acetaminophen) tablets using Acura’s LIMITx technology manufactured in the three New Drug Application (NDA) required registration batches passed testing at the twenty-four month time point in an ongoing shelf life study when stored at normal temperature and humidity conditions, also known as controlled room temperature. The patented LIMITx technology is a composition of inactive ingredients formulated in a manner that reduces the risks of drug overdose by reducing peak drug levels when excessive numbers of tablets are ingested. Two known hydrocodone derivatives continues to be detected in the CRT samples, as well as, unknown impurities. The unknown impurities remain at levels within standards typically accepted by the Food and Drug Administration (FDA) for such impurities but the levels have increased since the eighteen month analysis. They intend to continue the shelf life study with the CRT samples as previously planned. The LTX-03 tablets were produced at the commercial contract manufacturer, in the to-be-marketed formulation, at commercial (equipment and process) scale. The data being generated in the shelf life study is intended to be used to support the manufacturing and shelf life requirements for a NDA. FDA Guidance allows for the use of a minimum of 24 month CRT data to establish shelf life standards for a product. Recent reports suggest growing numbers of legitimate pain patients are going undertreated as they can no longer find doctors willing to treat them due to new prescribing guidelines associated with the opioid epidemic. Suicide is increasingly seen as the only remedy for some of these patients through opioid overdose. They goal with LIMITx is to develop a treatment for effective pain relief at a one or two tablet dose while providing overdose protection by limiting high peak levels of drug in the bloodstream (Cmax) that can lead to respiratory depression and death when more than the recommended dose is ingested. LIMITx works by neutralizing stomach acid with buffering ingredients as increasing numbers of tablets are swallowed thereby reducing the stomach acid available to cause the release and subsequent systemic absorption of the active ingredient from micro-particles contained in the LIMITx tablets. In a human clinical study, formulations of LTX-03 demonstrated, under fasted conditions, analgesic levels of hydrocodone in the blood when taken at a recommended one or two tablet dose but reduced the maximum blood level (Cmax) up to 30% when subjects were exposed to higher buffer ingredient levels. Hydrocodone with acetaminophen remains the single largest prescribed opioid in the U.S. with excess oral ingestion as the most prevalent method of misuse. Analysis of forensic data associated with hydrocodone overdose death suggests a typical consumption of approximately 16 immediate-release tablets, well within the number of tablets in an average filled opioid prescription. The Company intends to demonstrate that a meaningful reduction in Cmax associated with oral overdose can mitigate the risk of respiratory depression and death. LTX-03 may offer safety advantages over existing opioid therapies consistent with the FDA’s recently proposed new guidelines for the approval of opioid products.공고 • Aug 11Acura Pharmaceuticals, Inc. announced delayed 10-Q filingOn 08/10/2023, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • May 16Acura Pharmaceuticals, Inc. announced delayed 10-Q filingOn 05/15/2023, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • Feb 03Acura Pharmaceuticals, Inc. Announces First Clinical Study for Its Investigational Drug LTX-03Acura Pharmaceuticals, Inc. announced that the first clinical study for its investigational drug LTX-03 (hydrocodone bitartrate and acetaminophen) tablets using the company’s LIMITx technology commenced enrollment. The study, AP-LTX-311 or Study 311, is designed to evaluate the levels of hydrocodone and acetaminophen in the blood plasma when taken at doses in excess of normal therapeutic doses. The LIMITx technology is designed to minimize risks associated with overdose by lowering the maximum drug concentration of hydrocodone in the blood as increasing numbers of tablets are ingested. The Company expects topline results from Study 311 to be available in the second quarter of 2023. Study 311 is a phase 1 pharmacokinetic study in fasted healthy adult subjects who will be taking 2, 5 and 9 tablet doses. Study 311 is targeted to have 20 subjects complete all doses which will be administered in crossover fashion over a 4 week dosing period, with one week washout between doses. All subjects will receive an intravenous naloxone blockade during drug administration to negate the pharmacologic effects of the opioid hydrocodone. The Company expects to compare the results from the LTX-03 doses to the known, well-characterized pharmacokinetic results for hydrocodone and acetaminophen from the published literature with the intent to demonstrate lower levels of hydrocodone exposure for LTX-03 compared to the currently marketed comparator product as increasing number of tablets are ingested. The acetaminophen active ingredient is not incorporated into the LIMITx technology in the LTX-03 tablet and is not expected to be substantially different from the comparator product.공고 • Nov 05Acura Pharmaceuticals, Inc. announced delayed 10-Q filingOn 11/04/2022, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • Jul 20Acura Pharmaceuticals, Inc. announced that it has received $0.15 million in fundingAcura Pharmaceuticals, Inc. announced a private placement of loan for gross processed of $150,000 on July 18, 2022. The transaction included participation from existing investor John Schutte. The company issued an unsecured promissory note. The note bears interest at 5.25%, and matures on December 31, 2023, at which time all principal and interest is due. Events of default under the note include, among other items, bankruptcy events, failure to pay interest and principal when due and such failure continues for 5 days, and if Acura is generally not, or is unable to, or admits in writing its inability to, pay its debts as they become due. If any amount payable hereunder is not paid when due (without regard to any applicable grace periods), whether at stated maturity, by acceleration, or otherwise, including upon an event of default, such overdue amount shall bear interest at the rate per annum of 7.5% from the date of such non-payment until such amount is paid in full. The company received a total of $1,275,000 to date.공고 • May 17Acura Pharmaceuticals, Inc. announced delayed 10-Q filingOn 05/16/2022, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • Apr 01Acura Pharmaceuticals, Inc. announced delayed annual 10-K filingOn 03/31/2022, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공고 • Mar 03Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03Acura Pharmaceuticals, Inc. announced an amendment to its License, Development and Commercialization Agreement (“Agreement”) regarding Acura’s LIMITx™ LTX-03 product candidate with Abuse Deterrent Pharmaceuticals, LLC (“AD Pharma”) to extend the FDA Acceptance Date for LTX-03 (“NDA Acceptance Date”) to December 31, 2022. The Company expects to complete clinical studies and other required steps to file the NDA and gain regulatory acceptance by that date. Recent reports suggest growing numbers of legitimate pain patients are going undertreated as they can no longer find doctors willing to treat them due to new prescribing guidelines associated with the opioid epidemic. Suicide is increasingly seen as the only remedy for some of these patients through opioid overdose. Goal with LIMITx is to develop a treatment for effective pain relief at a one or two tablet dose while providing overdose protection by limiting high peak levels of drug in the bloodstream (Cmax) that can lead to respiratory depression and death when more than the recommended dose is ingested. LIMITx works by neutralizing stomach acid with buffering ingredients as increasing numbers of tablets are swallowed thereby reducing the stomach acid available to cause the release and subsequent systemic absorption of the active ingredient from micro-particles contained in the LIMITx tablets. In a human clinical study, formulations of LTX-03 demonstrated, under fasted conditions, analgesic levels of hydrocodone in the blood when taken at a recommended one or two tablet dose but reduced the maximum blood level (Cmax) up to 34% when subjects were exposed to higher buffer ingredient levels. Hydrocodone with acetaminophen remains the single largest prescribed opioid in the U.S. with excess oral ingestion as the most prevalent method of misuse. Clinical studies with hydromorphone (LTX-04) demonstrated reductions in Cmax of up to 65% when up to 8 tablets were ingested. Analysis of forensic data associated with hydrocodone overdose death suggests a typical consumption of approximately 16 immediate-release tablets, well within the number of tablets in an average filled opioid prescription. The Company intends to demonstrate that a meaningful reduction in Cmax associated with oral overdose can mitigate the risk of respiratory depression and death. LTX-03 may offer safety advantages over existing opioid therapies consistent with the Food and Drug Administration’s (FDA) recently proposed new guidelines for the approval of opioid products.공고 • Feb 15Acura Pharmaceuticals Provides Development Update on LTX-03Acura Pharmaceuticals, Inc. announced that the LTX-03 (hydrocodone bitartrate and acetaminophen) tablets using Acura’s LIMITx technology manufactured in the three New Drug Application (“NDA”) required registration batches successfully passed testing at the six month time point in an ongoing shelf life study when stored at normal temperature and humidity conditions, also known as controlled room temperature (“CRT”). The patented LIMITx technology is a composition of inactive ingredients formulated in a manner that reduces the risks of drug overdose by reducing peak drug levels when inappropriate numbers of tablets are ingested. When stored at high temperature and humidity, also known as accelerated conditions (“AC”), the six month tests revealed the presence of a known derivative of hydrocodone at levels requiring further testing. This known derivative was also detected in the CRT samples and intermediate condition (“IC”) samples, those stored at temperatures and humidity between CRT and AC, at levels within normally accepted limits at this stage of development. The company intends to continue the shelf life study with the CRT and IC samples as previously planned. The LTX-03 tablets were produced at the commercial contract manufacturer, in the to-be-marketed formulation, at commercial (equipment and process) scale. The data being generated in the shelf life study is intended to be used to support the manufacturing and shelf life requirements for an NDA. Acura has completed its review of the Advice Letter received in October 2021 from the Food and Drug Administration (“FDA”) regarding proposed clinical study program for LTX-03. The company updated the three pharmacokinetic study protocols submitted to the FDA and drafted a fourth pharmacokinetic study protocol based on the Advice Letter. These protocols have been provided to development and commercialization partner, Abuse Deterrent Pharmaceuticals, LLC (“AD Pharma”) for comment and determination of the timing of initiation of the studies. The new protocols will require submission to the FDA under the LTX-03 Investigational New Drug (“IND”) application before they can commence.공고 • Jun 08Acura Pharmaceuticals Provides Development Update on LTX-03Acura Pharmaceuticals, Inc. announced the successful completion of three NDA required registration batches of the to-be-marketed LTX-03 formulation. The LTX-03 tablets were manufactured on commercial scale equipment and passed all requisite quality assurance tests. The LTX-03 tablets from these batches will be used in a six month shelf life stability study, which will commence immediately, and in human clinical studies, which will commence after an update to the Investigation New Drug application on file with the Food and Drug Administration (FDA). LTX-03 (hydrocodone with acetaminophen): Recent reports suggest growing numbers of legitimate pain patients are going undertreated as they can no longer find doctors willing to treat them due to new prescribing guidelines associated with the opioid epidemic. Suicide is increasingly seen as the only remedy for some of these patients through opioid overdose. The company's goal with LIMITx is to develop a treatment for effective pain relief at a one or two tablet dose while providing overdose protection by limiting high peak levels of drug in the bloodstream (Cmax) that can lead to respiratory depression and death when more than the recommended dose is ingested. LIMITx works by neutralizing stomach acid with buffering ingredients as increasing numbers of tablets are swallowed thereby reducing the stomach acid available to cause the release and subsequent systemic absorption of the active ingredient from micro-particles contained in the LIMITx tablets. In a human clinical study, formulations of LTX-03 demonstrated, under fasted conditions, analgesic levels of hydrocodone in the blood when taken at a recommended one or two tablet dose but reduced the maximum blood level (Cmax) up to 34% when subjects were exposed to higher buffer ingredient levels. Hydrocodone with acetaminophen remains the single largest prescribed opioid in the U.S. with excess oral ingestion as the most prevalent method of misuse. Clinical studies with hydromorphone (LTX-04) demonstrated reductions in Cmax of up to 65% when up to 8 tablets were ingested. Analysis of forensic data associated with hydrocodone overdose death suggests a typical consumption of approximately 16 immediate-release tablets, well within the number of tablets in an average filled opioid prescription. The Company intends to demonstrate that a meaningful reduction in Cmax associated with oral overdose can mitigate the risk of respiratory depression and death. LTX-03 may offer safety advantages over existing opioid therapies consistent with the Food and Drug Administration’s (FDA) recently proposed new guidelines for the approval of opioid products.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 ACUR 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: ACUR 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Acura Pharmaceuticals 배당 수익률 vs 시장ACUR의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (ACUR)n/a시장 하위 25% (US)1.3%시장 상위 25% (US)4.1%업계 평균 (Pharmaceuticals)2.0%분석가 예측 (ACUR) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ACUR 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ACUR 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ACUR 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: ACUR 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/20 07:05종가2026/07/15 00:00수익2021/12/31연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Acura Pharmaceuticals, Inc.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Robert HazlettRoth Capital Partners
공고 • May 14Acura Pharmaceuticals, Inc. announced delayed 10-Q filingOn 05/13/2026, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • Mar 28Acura Pharmaceuticals, Inc. announced delayed annual 10-K filingOn 03/27/2026, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공고 • Mar 11Acura Pharmaceuticals, Inc. announced that it has received $0.1 million in fundingAcura Pharmaceuticals, Inc. announced a private placement of loan for a principal amount of $100,000 on March 10, 2026. The transaction included participation from returning lender, Abuse Deterrent Pharma, LLC. The company issued a secured promissory note. The note bears interest at 5.25%. The Events of default under the Note include, among other items, bankruptcy events, failure to pay interest and principal when due and such failure continues for 5 days, and if Acura is generally not, or is unable to, or admits in writing its inability to, pay its debts as those debts become due. If any amount payable hereunder is not paid when due (without regard to any applicable grace periods), whether at stated maturity, by acceleration, or otherwise, including upon an event of default, such overdue amount shall bear interest at the rate per annum of 7.5% from the date of such non-payment until such amount is paid in full. The company has received a total principal balance of $9,894,279.
공고 • Nov 23Acura Pharmaceuticals, Inc. announced delayed 10-Q filingOn 11/21/2025, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • Sep 04Acura Pharmaceuticals, Inc. announced that it has received $8.694279 million in funding from Abuse Deterrent Pharma, LLCAcura Pharmaceuticals, Inc. announced a private placement of loan for a principal amount of $100,000 on September 3, 2025. The transaction included participation from returning lender, Abuse Deterrent Pharma, LLC. The company issued a secured promissory note. The note bears interest at 5.25%. The Events of default under the Note include, among other items, bankruptcy events, failure to pay interest and principal when due and such failure continues for 5 days, and if Acura is generally not, or is unable to, or admits in writing its inability to, pay its debts as those debts become due. If any amount payable hereunder is not paid when due (without regard to any applicable grace periods), whether at stated maturity, by acceleration, or otherwise, including upon an event of default, such overdue amount shall bear interest at the rate per annum of 7.5% from the date of such non-payment until such amount is paid in full. The company has received a total principal balance of $8,694,279.
공고 • Aug 20Acura Pharmaceuticals, Inc. announced delayed 10-Q filingOn 08/19/2025, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • May 23Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Announces Second Meeting with US Food and Drug AdministrationAcura Pharmaceuticals, Inc. reported that on May 15, 2025 the Company and its development partner, AbuseDeterrent Pharma, LLC, had a second meeting with the US Food and Drug Administration (FDA) regarding further development requirements for its drug candidate LTX-03 (hydrocodone bitartrate and acetaminophen) tablets to progress toward a New Drug Application (NDA) submission. LTX-03 uses Acura's LIMITx technology that is designed to provide incrementally lower, non-linear peak drug blood concentrations (Cmax) of hydrocodone as additional tablets are ingested. Subject to the final FDA meeting minutes and further deliberations and analyses by the Companies, expect to conduct one additional human pharmacokinetic study of a single tablet dose of LTX-03 compared to a single FDA Reference Standard drug in the fed and fasted state. This study, designated AP-LTX-310, will commence following production of new clinical supplies of LTX-03. Subject to NDA review, FDA was amenable to describing the unique pharmacokinetic characteristics of LTX-03 in the final approved labeling. FDA advised that a label claim suggesting a lower risk of overdose would not be warranted by pharmacokinetic testing alone. The Company believes a study to support a lower risk safety claim would best be accomplished post-NDA approval, which cannot be assured. FDA indicated the lower 5/325mg and 7.5/325mg dosage strengths of LTX-03 will require a plan to scientifically support those products in the NDA. The company is evaluating whether to conduct such a study for the NDA submission or to study and add these strengths after NDA approval, which cannot be assurance. LTX-03 (hydocodone with acetaminophen) The incidence and severity of side effects, such as nausea, vomiting and respiratory depression, associated with opioid pain relievers, such as hydrocodone, increase with increased blood plasma concentration of the opioid. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements expressed or implied by such forward-looking statements.
공고 • May 15Acura Pharmaceuticals, Inc. announced delayed 10-Q filingOn 05/14/2025, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • Mar 27Acura Pharmaceuticals, Inc. announced delayed annual 10-K filingOn 03/26/2025, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공고 • Nov 22Acura Pharmaceuticals, Inc. announced delayed 10-Q filingOn 11/21/2024, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • Aug 10Acura Pharmaceuticals, Inc. announced delayed 10-Q filingOn 08/09/2024, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • May 17Acura Pharmaceuticals, Inc. announced delayed 10-Q filingOn 05/15/2024, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • Apr 02Acura Pharmaceuticals, Inc. announced delayed annual 10-K filingOn 04/01/2024, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공고 • Feb 15Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in fundingAcura Pharmaceuticals, Inc. announced a private placement of loan for gross processed of $250,000 on February 14, 2024. The transaction included participation from returning lender Abuse Deterrent Pharma, LLC. The company issued an unsecured promissory note. The note bears interest at 5.25%, and matures on March 31, 2024, at which time all principal and interest is due. Events of default under the note include, among other items, bankruptcy events, failure to pay interest and principal when due and such failure continues for 5 days, and if company is generally not, or is unable to, or admits in writing its inability to, pay its debts as they become due. If any amount payable hereunder is not paid when due (without regard to any applicable grace periods), whether at stated maturity, by acceleration, or otherwise, including upon an event of default, such overdue amount shall bear interest at the rate per annum of 7.5% from the date of such non-payment until such amount is paid in full. the company received a total of $5,169,279.
공고 • Nov 04Acura Pharmaceuticals, Inc. announced delayed 10-Q filingOn 11/03/2023, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • Sep 26Acura Pharmaceuticals, Inc. Announces Retirement and Resignation of Mr. Bruce F. (Toby) Wesson as Member of Board of DirectorsEffective September 22, 2023, Mr. Bruce F. (Toby) Wesson retired and resigned as a member of Board of Directors and the Board of Directors of Acura Pharmaceutical Technologies, Inc. subsidiary. Mr. Wesson has agreed to serve as Director Emeritus following his resignation. In such capacity, Mr. Wesson may attend Board and Committee meetings and participate in the discussion of matters at such meetings, but he will not have voting rights on any such matters. Mr. Wesson has been a member of Board of Directors since March 1998. From January 1991 until June 30, 2011, Mr. Wesson was a Partner of Galen Associates, a health care venture firm, and a General Partner of Galen Partners III, L.P. Prior to January 1991, he was Senior Vice President and Managing Director of Smith Barney, Harris Upham & Co. Inc., an investment banking firm. From May 2006 until June 2016 he served on the Board of Derma Sciences, Inc. From June 1999 until January 2016 he served as director of the Board of MedAssets, Inc. and for over eight years until January 2016 served as Vice Chairman of MedAssets, Inc. Mr. Wesson earned a Bachelor of Arts degree from Colgate University and a Masters of Business Administration from Columbia University. As a member of Acura's Board, Mr. Wesson helped to oversee the transformation of Acura from a troubled generic pharmaceutical manufacturer to an innovative specialty pharmaceutical company.
공고 • Sep 02Acura Pharmaceuticals, Inc. Provides Update Related to LTX-03 (Hydrocodone Bitartrate and Acetaminophen) TabletsAcura Pharmaceuticals, Inc. reported that the LTX-03 (hydrocodone bitartrate and acetaminophen) tablets using Acura’s LIMITx technology manufactured in the three New Drug Application (NDA) required registration batches passed testing at the twenty-four month time point in an ongoing shelf life study when stored at normal temperature and humidity conditions, also known as controlled room temperature. The patented LIMITx technology is a composition of inactive ingredients formulated in a manner that reduces the risks of drug overdose by reducing peak drug levels when excessive numbers of tablets are ingested. Two known hydrocodone derivatives continues to be detected in the CRT samples, as well as, unknown impurities. The unknown impurities remain at levels within standards typically accepted by the Food and Drug Administration (FDA) for such impurities but the levels have increased since the eighteen month analysis. They intend to continue the shelf life study with the CRT samples as previously planned. The LTX-03 tablets were produced at the commercial contract manufacturer, in the to-be-marketed formulation, at commercial (equipment and process) scale. The data being generated in the shelf life study is intended to be used to support the manufacturing and shelf life requirements for a NDA. FDA Guidance allows for the use of a minimum of 24 month CRT data to establish shelf life standards for a product. Recent reports suggest growing numbers of legitimate pain patients are going undertreated as they can no longer find doctors willing to treat them due to new prescribing guidelines associated with the opioid epidemic. Suicide is increasingly seen as the only remedy for some of these patients through opioid overdose. They goal with LIMITx is to develop a treatment for effective pain relief at a one or two tablet dose while providing overdose protection by limiting high peak levels of drug in the bloodstream (Cmax) that can lead to respiratory depression and death when more than the recommended dose is ingested. LIMITx works by neutralizing stomach acid with buffering ingredients as increasing numbers of tablets are swallowed thereby reducing the stomach acid available to cause the release and subsequent systemic absorption of the active ingredient from micro-particles contained in the LIMITx tablets. In a human clinical study, formulations of LTX-03 demonstrated, under fasted conditions, analgesic levels of hydrocodone in the blood when taken at a recommended one or two tablet dose but reduced the maximum blood level (Cmax) up to 30% when subjects were exposed to higher buffer ingredient levels. Hydrocodone with acetaminophen remains the single largest prescribed opioid in the U.S. with excess oral ingestion as the most prevalent method of misuse. Analysis of forensic data associated with hydrocodone overdose death suggests a typical consumption of approximately 16 immediate-release tablets, well within the number of tablets in an average filled opioid prescription. The Company intends to demonstrate that a meaningful reduction in Cmax associated with oral overdose can mitigate the risk of respiratory depression and death. LTX-03 may offer safety advantages over existing opioid therapies consistent with the FDA’s recently proposed new guidelines for the approval of opioid products.
공고 • Aug 11Acura Pharmaceuticals, Inc. announced delayed 10-Q filingOn 08/10/2023, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • May 16Acura Pharmaceuticals, Inc. announced delayed 10-Q filingOn 05/15/2023, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • Feb 03Acura Pharmaceuticals, Inc. Announces First Clinical Study for Its Investigational Drug LTX-03Acura Pharmaceuticals, Inc. announced that the first clinical study for its investigational drug LTX-03 (hydrocodone bitartrate and acetaminophen) tablets using the company’s LIMITx technology commenced enrollment. The study, AP-LTX-311 or Study 311, is designed to evaluate the levels of hydrocodone and acetaminophen in the blood plasma when taken at doses in excess of normal therapeutic doses. The LIMITx technology is designed to minimize risks associated with overdose by lowering the maximum drug concentration of hydrocodone in the blood as increasing numbers of tablets are ingested. The Company expects topline results from Study 311 to be available in the second quarter of 2023. Study 311 is a phase 1 pharmacokinetic study in fasted healthy adult subjects who will be taking 2, 5 and 9 tablet doses. Study 311 is targeted to have 20 subjects complete all doses which will be administered in crossover fashion over a 4 week dosing period, with one week washout between doses. All subjects will receive an intravenous naloxone blockade during drug administration to negate the pharmacologic effects of the opioid hydrocodone. The Company expects to compare the results from the LTX-03 doses to the known, well-characterized pharmacokinetic results for hydrocodone and acetaminophen from the published literature with the intent to demonstrate lower levels of hydrocodone exposure for LTX-03 compared to the currently marketed comparator product as increasing number of tablets are ingested. The acetaminophen active ingredient is not incorporated into the LIMITx technology in the LTX-03 tablet and is not expected to be substantially different from the comparator product.
공고 • Nov 05Acura Pharmaceuticals, Inc. announced delayed 10-Q filingOn 11/04/2022, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • Jul 20Acura Pharmaceuticals, Inc. announced that it has received $0.15 million in fundingAcura Pharmaceuticals, Inc. announced a private placement of loan for gross processed of $150,000 on July 18, 2022. The transaction included participation from existing investor John Schutte. The company issued an unsecured promissory note. The note bears interest at 5.25%, and matures on December 31, 2023, at which time all principal and interest is due. Events of default under the note include, among other items, bankruptcy events, failure to pay interest and principal when due and such failure continues for 5 days, and if Acura is generally not, or is unable to, or admits in writing its inability to, pay its debts as they become due. If any amount payable hereunder is not paid when due (without regard to any applicable grace periods), whether at stated maturity, by acceleration, or otherwise, including upon an event of default, such overdue amount shall bear interest at the rate per annum of 7.5% from the date of such non-payment until such amount is paid in full. The company received a total of $1,275,000 to date.
공고 • May 17Acura Pharmaceuticals, Inc. announced delayed 10-Q filingOn 05/16/2022, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • Apr 01Acura Pharmaceuticals, Inc. announced delayed annual 10-K filingOn 03/31/2022, Acura Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공고 • Mar 03Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03Acura Pharmaceuticals, Inc. announced an amendment to its License, Development and Commercialization Agreement (“Agreement”) regarding Acura’s LIMITx™ LTX-03 product candidate with Abuse Deterrent Pharmaceuticals, LLC (“AD Pharma”) to extend the FDA Acceptance Date for LTX-03 (“NDA Acceptance Date”) to December 31, 2022. The Company expects to complete clinical studies and other required steps to file the NDA and gain regulatory acceptance by that date. Recent reports suggest growing numbers of legitimate pain patients are going undertreated as they can no longer find doctors willing to treat them due to new prescribing guidelines associated with the opioid epidemic. Suicide is increasingly seen as the only remedy for some of these patients through opioid overdose. Goal with LIMITx is to develop a treatment for effective pain relief at a one or two tablet dose while providing overdose protection by limiting high peak levels of drug in the bloodstream (Cmax) that can lead to respiratory depression and death when more than the recommended dose is ingested. LIMITx works by neutralizing stomach acid with buffering ingredients as increasing numbers of tablets are swallowed thereby reducing the stomach acid available to cause the release and subsequent systemic absorption of the active ingredient from micro-particles contained in the LIMITx tablets. In a human clinical study, formulations of LTX-03 demonstrated, under fasted conditions, analgesic levels of hydrocodone in the blood when taken at a recommended one or two tablet dose but reduced the maximum blood level (Cmax) up to 34% when subjects were exposed to higher buffer ingredient levels. Hydrocodone with acetaminophen remains the single largest prescribed opioid in the U.S. with excess oral ingestion as the most prevalent method of misuse. Clinical studies with hydromorphone (LTX-04) demonstrated reductions in Cmax of up to 65% when up to 8 tablets were ingested. Analysis of forensic data associated with hydrocodone overdose death suggests a typical consumption of approximately 16 immediate-release tablets, well within the number of tablets in an average filled opioid prescription. The Company intends to demonstrate that a meaningful reduction in Cmax associated with oral overdose can mitigate the risk of respiratory depression and death. LTX-03 may offer safety advantages over existing opioid therapies consistent with the Food and Drug Administration’s (FDA) recently proposed new guidelines for the approval of opioid products.
공고 • Feb 15Acura Pharmaceuticals Provides Development Update on LTX-03Acura Pharmaceuticals, Inc. announced that the LTX-03 (hydrocodone bitartrate and acetaminophen) tablets using Acura’s LIMITx technology manufactured in the three New Drug Application (“NDA”) required registration batches successfully passed testing at the six month time point in an ongoing shelf life study when stored at normal temperature and humidity conditions, also known as controlled room temperature (“CRT”). The patented LIMITx technology is a composition of inactive ingredients formulated in a manner that reduces the risks of drug overdose by reducing peak drug levels when inappropriate numbers of tablets are ingested. When stored at high temperature and humidity, also known as accelerated conditions (“AC”), the six month tests revealed the presence of a known derivative of hydrocodone at levels requiring further testing. This known derivative was also detected in the CRT samples and intermediate condition (“IC”) samples, those stored at temperatures and humidity between CRT and AC, at levels within normally accepted limits at this stage of development. The company intends to continue the shelf life study with the CRT and IC samples as previously planned. The LTX-03 tablets were produced at the commercial contract manufacturer, in the to-be-marketed formulation, at commercial (equipment and process) scale. The data being generated in the shelf life study is intended to be used to support the manufacturing and shelf life requirements for an NDA. Acura has completed its review of the Advice Letter received in October 2021 from the Food and Drug Administration (“FDA”) regarding proposed clinical study program for LTX-03. The company updated the three pharmacokinetic study protocols submitted to the FDA and drafted a fourth pharmacokinetic study protocol based on the Advice Letter. These protocols have been provided to development and commercialization partner, Abuse Deterrent Pharmaceuticals, LLC (“AD Pharma”) for comment and determination of the timing of initiation of the studies. The new protocols will require submission to the FDA under the LTX-03 Investigational New Drug (“IND”) application before they can commence.
공고 • Jun 08Acura Pharmaceuticals Provides Development Update on LTX-03Acura Pharmaceuticals, Inc. announced the successful completion of three NDA required registration batches of the to-be-marketed LTX-03 formulation. The LTX-03 tablets were manufactured on commercial scale equipment and passed all requisite quality assurance tests. The LTX-03 tablets from these batches will be used in a six month shelf life stability study, which will commence immediately, and in human clinical studies, which will commence after an update to the Investigation New Drug application on file with the Food and Drug Administration (FDA). LTX-03 (hydrocodone with acetaminophen): Recent reports suggest growing numbers of legitimate pain patients are going undertreated as they can no longer find doctors willing to treat them due to new prescribing guidelines associated with the opioid epidemic. Suicide is increasingly seen as the only remedy for some of these patients through opioid overdose. The company's goal with LIMITx is to develop a treatment for effective pain relief at a one or two tablet dose while providing overdose protection by limiting high peak levels of drug in the bloodstream (Cmax) that can lead to respiratory depression and death when more than the recommended dose is ingested. LIMITx works by neutralizing stomach acid with buffering ingredients as increasing numbers of tablets are swallowed thereby reducing the stomach acid available to cause the release and subsequent systemic absorption of the active ingredient from micro-particles contained in the LIMITx tablets. In a human clinical study, formulations of LTX-03 demonstrated, under fasted conditions, analgesic levels of hydrocodone in the blood when taken at a recommended one or two tablet dose but reduced the maximum blood level (Cmax) up to 34% when subjects were exposed to higher buffer ingredient levels. Hydrocodone with acetaminophen remains the single largest prescribed opioid in the U.S. with excess oral ingestion as the most prevalent method of misuse. Clinical studies with hydromorphone (LTX-04) demonstrated reductions in Cmax of up to 65% when up to 8 tablets were ingested. Analysis of forensic data associated with hydrocodone overdose death suggests a typical consumption of approximately 16 immediate-release tablets, well within the number of tablets in an average filled opioid prescription. The Company intends to demonstrate that a meaningful reduction in Cmax associated with oral overdose can mitigate the risk of respiratory depression and death. LTX-03 may offer safety advantages over existing opioid therapies consistent with the Food and Drug Administration’s (FDA) recently proposed new guidelines for the approval of opioid products.